Literature DB >> 12631014

The Finnish evidence-based guideline for open-angle glaucoma.

A Tuulonen1, P J Airaksinen, E Erola, E Forsman, K Friberg, M Kaila, A Klemetti, M Mäkelä, P Oskala, P Puska, L Suoranta, H Teir, H Uusitalo, E Vainio-Jylhä, M-L Vuori.   

Abstract

In most patients, chronic open-angle glaucoma is a slowly progressive disease. Eyes with very high intraocular pressure (IOP > 30 mmHg) represent an exception to this and should be treated and followed extremely intensively. As lowering IOP is, so far, the only means of treating glaucoma, the majority of research reports deal with the IOP-lowering effect of the treatment. The primary goal of treatment, however, is to prevent glaucomatous damage to the structures and function of the eye. The effectiveness of treatment is monitored with optic disc and retinal nerve fibre layer imaging and with visual field examinations. If the glaucomatous changes are progressing, more effective treatment should be given. In the course of follow-up, it should be noted that the changes in the optic nerve structure and function appear and progress at different time-points with delays of up to several years. The assessment of abnormalities is dependent on the examination method and requires a great deal of experience on the part of the examiner. The important risk factors in glaucoma are elevated IOP (even if IOP is within normal range in half of patients ), age, positive family history, exfoliation, race and myopia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631014     DOI: 10.1034/j.1600-0420.2003.00021.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  16 in total

1.  Biomarkers for glaucoma: from the lab to the clinic.

Authors:  N Von Thun Und Hohenstein-Blaul; S Kunst; N Pfeiffer; F H Grus
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

Review 2.  Chronic open-angle glaucoma. Review for primary care physicians.

Authors:  Feisal A Adatia; Karim F Damji
Journal:  Can Fam Physician       Date:  2005-09       Impact factor: 3.275

Review 3.  Oxidative stress and potential applications of free radical scavengers in glaucoma.

Authors:  Mutay Aslan; Serdar Dogan; Ertan Kucuksayan
Journal:  Redox Rep       Date:  2013-03-06       Impact factor: 4.412

4.  Routine eye examinations for persons 20-64 years of age: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-07-01

5.  Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment.

Authors:  Eleonore Savatovsky; Jean-Claude Mwanza; Donald L Budenz; William J Feuer; Ruth Vandenbroucke; Joyce C Schiffman; Douglas R Anderson
Journal:  Ophthalmology       Date:  2014-09-07       Impact factor: 12.079

6.  Angiotensin(1-7) and ACE2, "The Hot Spots" of Renin-Angiotensin System, Detected in the Human Aqueous Humor.

Authors:  Mervi Holappa; Jarkko Valjakka; Anu Vaajanen
Journal:  Open Ophthalmol J       Date:  2015-03-31

7.  Adjusted color probability codes for peripapillary retinal nerve fiber layer thickness in healthy Koreans.

Authors:  Samin Hong; Sang-Myung Kim; Kyoungsoo Park; Jun Mo Lee; Chan Yun Kim; Gong Je Seong
Journal:  BMC Ophthalmol       Date:  2014-03-29       Impact factor: 2.209

8.  Correlation analysis between central corneal thickness and intraocular pressure in juveniles in Northern China: the Jinan city eye study.

Authors:  Wen Wei; Zhaoshan Fan; Lihua Wang; Zhiwei Li; Wanzhen Jiao; Yun Li
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

9.  Morphology of optic disc through heidelberg retina tomograph in retinal vein occlusions alone or in combination with primary open angle glaucoma.

Authors:  Alessandro Guido Actis; Luca Belli; Laura Dall'orto; Rachele Penna; Beatrice Brogliatti; Teresa Rolle
Journal:  Open Ophthalmol J       Date:  2013-07-26

10.  The Northern Finland Birth Cohort Eye Study: Design and baseline characteristics.

Authors:  Ville Saarela; Elina Karvonen; Katri Stoor; Pasi Hägg; Marja Luodonpää; Jaana Kuoppala; Anja Taanila; Anja Tuulonen
Journal:  BMC Ophthalmol       Date:  2013-10-08       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.